Trials / Conditions / ER+ HER2- Advanced Breast Cancer
ER+ HER2- Advanced Breast Cancer
7 registered clinical trials studyying ER+ HER2- Advanced Breast Cancer — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone NCT06188520 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Study of TFX06 in Women With Advanced Breast Cancer. NCT05927779 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer NCT05103826 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer NCT04541433 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. NCT03616587 | AstraZeneca | Phase 1 |
| Terminated | SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer NCT03596658 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | AZD9496 First Time in Patients Ascending Dose Study NCT02248090 | AstraZeneca | Phase 1 |